In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, achieved an overall response rate of 72% ...
New findings reveal promising advancements in treating relapsed mantle cell lymphoma with BCL-2 inhibitors and novel agents, ...
China’s National Medical Products Administration cleared Ascentage Pharma Group Corp. Ltd. to begin a registrational phase III trial of its BCL-2 selective inhibitor lisaftoclax (APG-2575) in ...
These preliminary clinical data show that the third-generation BCR-ABL1 inhibitor, olverembatinib, in combination with the novel Bcl-2 inhibitor, lisaftoclax, without chemotherapy or immunotherapy, ...
Scientists discovered which tumor cells resist treatment and why. By characterizing B-cells' developmental stages, they designed and tested a drug combination to effectively treat resistant B-cell ...
The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care. FDA granted ...
Covalent BTK inhibitors and Bcl-2 inhibitors are primary treatments for CLL, but alternatives are needed for relapsed or refractory cases. Treatment sequencing is vital, with potential switches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback